相关实验视频

Updated: Jun 22, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

使用澳大利亚制药福利计划 (PBS) 数据集的CLL患者的现实世界治疗模式和结果

Constantine Tam^1,2, Fei-Li Zhao³, Safee Azam⁴

¹The Alfred Hospital, Melbourne, Australia.

Leukemia & lymphoma

|July 5, 2024

概括

澳大利亚的慢性淋巴细胞白血病 (CLL) 治疗新型疗法已经显著转变. 这项研究观察到一线和复发性/耐药性CLL疗法的变化,到2021年,新的药物变得越来越常见.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

慢性淋巴细胞白血病 (CLL) 治疗随着新型向治疗的引入而发展.
了解治疗模式对于优化患者的治疗结果和资源配置至关重要.

研究的目的:

调查2011年至2021年澳大利亚CLL治疗模式的变化.
分析一线 (1L) 和复发/耐药 (R/R) CLL 疗法,治疗持续时间和整体存活率 (OS) 的变化.

主要方法:

使用澳大利亚制药福利计划 (PBS) 数据进行的回顾性队列研究.
包括803名在2011年1月1日至2021年7月31日期间接受首次PBS补偿的CLL药物治疗的患者.
对治疗线路,治疗时间,治疗持续时间和操作系统的分析.

主要成果:

第一线的CLL治疗从2011年的fludarabine,cyclophosphamide和rituximab (FCR) 转移到2021年的ambucil±CD20,Bruton Tyrosine Kinase抑制剂 (BTKi) 和CD20单疗法.
复发性/耐药性CLL治疗从CD20单疗或FCR演变为主要BTKi (57.7%) 和venetoclax±CD20 (26.1%) 到2021年.
与第一线治疗中的FCR相比,对CD20单疗和ambucil±CD20观察到较短的治疗持续时间.

结论:

引入新型疗法极大地改变了澳大利亚的CLL治疗模式.
目前的治疗模式反映了在第一线和复发/耐药环境中向BTKi和venetoclax等向药物的重大转变.
需要进一步的研究来评估这些不断变化的治疗策略对患者生存和生活质量的长期影响.

关键词:

慢性淋巴细胞白血病慢性淋巴细胞白血病布鲁顿铁氨酸激酶抑制剂现实世界的研究研究.

更多相关视频

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...